as seen in Targeting Trends Newsletter, Jan-Feb-Mar 2004
Progress continues to be made in moving SP-SAP closer to clinical trials as a treatment for chronic pain. The latest development is the leasing of a 3700-sq ft facility adjacent to the current ATS facility in San Diego.
This facility will be converted to GMP (Good Manufacturing Practice) space suitable for production of SP-SAP for use in Phase I/II human clinical trials. The site plan includes space for Class 10,000 clean rooms and quality control laboratories.
Early in March, the first of two GLP (Good Laboratory Practice) toxicology studies will begin. Dr. Jeff Allen will be leading this study at the University of California facility in San Diego. The UCSD toxicology studies are under the supervision of Dr. Tony Yaksh, who has expertise in the study of the effects of intrathecal delivery of pain medications.